Podcasts about Lymphoma

In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immunoglobulin class switching and suppressed lung fibrosis. Accordingly, TET3 may be a new therapeutic target in chronic GVHD. After that: rilzabrutinib, a BTK inhibitor for ITP. In a randomized, placebo-controlled trial, treatment produced rapid and durable platelet responses, with acceptable safety, in adults with immune thrombocytopenia who had failed multiple previous therapies. Finally: exploring pre-TCR surface expression patterns in T-cell ALL. Co-inhibition of the interleukin-7 receptor and pre-T cell receptor pathways may play a therapeutic role for a subset of T-lymphoblastic leukemias.Featured Articles: Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHDSafety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 studySurface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL

In this special episode, Dr. Shaji Kumar from the Mayo Clinic speaks with Blood editor Dr. Laurie Sehn on a paper recently published in Blood, "Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma". The findings demonstrate eliminating the need for sequential confirmation of response in multiple myeloma. The study, involving 583 episodes of progression, found that simultaneous confirmation of disease progression using two different markers (e.g., serum protein electrophoresis and serum free light chain assay) was 98% accurate, compared to 82% for sequential confirmation. This suggests that simultaneous confirmation could improve clinical trial accuracy and reduce false censoring. The International Myeloma Working Group is set to revise its response criteria to incorporate these findings, potentially simplifying disease assessment and reducing the need for multiple blood draws.

In this week's episode, we'll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics, cyclophosphamide as a treatment for non-immune effector cell-associated neurotoxicity in patients treated with B-cell maturation antigen, or BCMA, targeted CAR T-cell therapies, and how differences in glycosylation affect the clearance of human plasma-derived and recombinant von Willebrand factor concentrates.Featured Articles:Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcomeCyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatmentEnhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF

In this How I Treat Series episode Dr. Thomas Ortel leads a discussion with author Dr. Patrick Foy on his paper “How I diagnose and treat thrombocytopenia in geriatric patients”. See the full How I Treat series on geriatric hematology in volume 143 issue 3 of Blood Journal.

Mike is out of town, so Jim brought in one of Third Street Barbell's most consistent and inspirational members, Josh Hajar.Josh is an emergency department nurse who faced a harrowing fight with non-Hodgkin's Lymphoma, and then suffered an injury that set back his recovery and fitness goals. When he arrived at Third Street, he was finally ready to execute a winning game plan for losing weight and getting stronger. Building on the advice he received when he first received his cancer diagnosis to “Be Positive,” Josh sets a strong example in and out of the gym.Join our Discord for free at goodcompanydiscord.com!Check out our gym (Third Street Barbell) at ThirdStreetBarbell.com https://www.thirdstreetbarbell.com/ and subscribe for updates about our apparel line at goodcompanyapparel.com https://3sb.co/! Local memberships and international fresh fits! Get early access to our NEXT DROP!Check out our podcast website: 50percentfacts.com https://www.50percentfacts.com/50% Facts is a Spreaker Prime podcast on OCN – the Obscure Celebrity Network.____Hosted by Mike Farr (@silentmikke) https://www.instagram.com/silentmikke/ and Jim McDonald (@thejimmcd). https://www.instagram.com/thejimmcd/Produced by Jim McDonaldProduction assistance by Sam McDonald and Sebastian Brambila.Theme by Aaron Moore. Show art by Joseph Manzo (@jmanzo523)Become a supporter of this podcast: https://www.spreaker.com/podcast/50-facts-with-silent-mike-jim-mcd--5538735/support.

Today on The Hormone Genius Podcast, we are so excited to welcome Maddy Pollack—a passionate Integrative Nutrition Health Coach, Hormone Health Coach, and Yoga Instructor who specializes in helping women take control of their menstrual and hormonal health naturally. Maddy's journey is incredibly powerful. At just 24 years old, she was diagnosed with Stage 2 Hodgkin's Lymphoma. That life-altering experience sparked a deep curiosity and commitment to understanding the why behind her illness—and ultimately led her to uncover the often-overlooked connection between nutrition, hormone balance, and emotional wellness. Now fully in remission, Maddy dedicates her work to guiding women in naturally reducing PMS symptoms, balancing their hormones, releasing stubborn weight, and reconnecting with their bodies—without relying on medication. In our conversation today, we dive into: The missing link between traditional medical treatment and nutritional healing How to naturally regulate your cycle and ease PMS, and heal from PCOS The impact of stress, gut health, and lifestyle on hormone function Practical, empowering tips for working with your cycle instead of against it Maddy brings a compassionate, science-informed approach to wellness, and I know our listeners are going to walk away with so many actionable insights.

Primary Central Nervous System Lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain, spinal cord, or… The post Breaking Down Primary CNS Lymphoma: From Rare Diagnosis to Growing Progress first appeared on The Bloodline with LLS.

In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: venetoclax-based induction therapy in younger patients with AML. Venetoclax plus decitabine was associated with superior safety and non-inferior response rates compared to intensive chemotherapy. Is it time to consider lower-intensity therapy beyond older and unfit patients? Finally, a focus on venous thromboembolism. Researchers link BGAT, an enzyme pivotal to determining blood type, to risk of future VTE. They say high plasma levels of BGAT contribute to risk above and beyond what can be explained by von Willebrand factor and Factor VIII.Featured Articles:One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying themVenetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AMLHisto–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study

Dr. Doug Thamm discusses the development and use of Tanovea, a drug for treating lymphoma in dogs. He explains the drug's origins, initially researched as a human cancer therapeutic in collaboration with Gilead Sciences, and its transition to veterinary use.   Dr. Thamm provides insights into Tanovea's application, dosage, and effectiveness compared to the CHOP protocol, as well as its potential side effects and other possible uses in different cancer types like multiple myeloma. The episode also delves into related immunotherapy research and personal reflections from Dr. Thamm, a double cancer survivor, on his career choice in veterinary oncology. Your Voice Matters!   If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Videos:  https://www.youtube.com/watch?v=G0iRyKshzq8  Related Links:  Our article on lymphoma: https://www.dogcancer.com/articles/types-of-dog-cancer/lymphoma-in-dogs/  Our article on Tanovea: https://www.dogcancer.com/articles/drugs/tanovea-rabacfosadine-chemotherapy/  Get the facts on dog cancer remission: https://www.dogcancer.com/articles/stats-and-facts/dog-cancer-remission/  Chapters:  00:00 Introduction  00:13 Interview with Dr. Doug Thamm  00:26 The Early Involvement with Tanovea  00:41 Challenges and Discoveries in Drug Development  02:16 Transition from Human to Veterinary Use  02:48 Clinical Trials and Dosage Experiments  06:45 FDA Approval and Practical Use  08:05 Comparing Tanovea and CHOP Protocol  15:23 Exploring Alternative Treatments: Laverdia  18:43 Off-Label Uses and Future Research  23:46 Exploring Tanovea's Effectiveness in Blood Cancers  25:14 Cost Comparison: Tanovea vs. CHOP  26:15 Side Effects of Tanovea  28:47 Pulmonary Fibrosis and Breed-Specific Risks  32:52 Personal Cancer Journeys: Dr. Doug and His Wife  38:23 Debunking Myths About Dog Cancer Treatment  42:24 The Future of Cancer Treatment: Immunotherapy  45:23 Conclusion and Resources    Get to know Dr. Doug Thamm: https://www.dogcancer.com/people/doug-Thammm-v-m-d-diplomate-acvim-oncology/   For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/   Learn more about your ad choices. Visit megaphone.fm/adchoices

In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie Callium, Keyvan Karkouti, and Ron George.Find the full published review series in Volume 145 Issue 20 of Blood Journal.

In this week's episode we'll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma.Featured ArticlesClonal Hematopoiesis Landscape in Frequent Blood DonorsIntegrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody responseUpfront Blinatumomab Improves MRD Clearance and Outcome in Adult Ph-negative B-lineage ALL: The GIMEMA LAL2317 Phase 2 Study

BUFFALO, NY – May 19, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 9, 2025, titled “Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies.” In this study, a team from Foresight Diagnostics led by first author Nina Klimova and corresponding author Laura Hyland validated a new DNA-based blood test designed to detect minimal residual disease (MRD) in patients with B-cell cancers. This assay uses a highly sensitive method called Phased Variant Enrichment and Detection Sequencing (PhasED-Seq) to find tiny fragments of tumor DNA in the blood. Its ultra-sensitive detection capabilities offer a powerful tool for early cancer detection, monitoring treatment response, and predicting cancer reappearance. B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL), are among the most prevalent blood cancers. Although many patients respond to initial treatment, up to 40% relapse. Standard monitoring methods such as imaging scans often miss low levels of cancer cells, creating a need for more precise tools. This study introduces a non-invasive blood test that improves the detection of MRD, a critical factor in guiding follow-up care and early intervention. The test works by tracking unique groups of mutations known as phased variants in tumor DNA. These mutations are more specific to cancer and allow for highly accurate identification of tumor fragments in the bloodstream. The PhasED-Seq-based MRD assay was tested on three types of samples. First, blood plasma from healthy individuals was used to confirm the test does not give false positives. Second, researchers created controlled samples by mixing tumor DNA from lymphoma patients with healthy DNA to measure how sensitive and precise the test is. Finally, blood samples from patients with B-cell lymphoma were used to compare the new test to an existing method. Across all sample types, the PhasED-Seq-based MRD assay demonstrated exceptional performance—capable of detecting fewer than one cancer DNA molecule per million normal DNA fragments. It also demonstrated a very low false positive rate and over 96% reproducibility across different laboratory conditions. Compared to an existing method, the new PhasED-Seq assay showed more than 90% agreement in positive results and nearly 78% agreement in negative results. In cases where the tests disagreed, the new method aligned more closely with actual clinical outcomes, including whether patients relapsed or stayed in remission. “The background error rate of the PhasED-Seq-based MRD assay was 1.95E-08, or 1.95 mutant molecules in 100 million informative molecules.” The findings support the use of PhasED-Seq-based MRD assays in routine clinical practice. It could be especially useful for identifying patients who need additional treatment even when imaging results appear normal. This aligns with updated clinical guidelines that encourage the use of blood-based DNA tests to supplement traditional scans in lymphoma care. This study offers strong evidence that the PhasED-Seq-based MRD assay is a precise, reliable, and clinically relevant tool. By detecting signs of cancer earlier and more accurately, it may help clinicians tailor treatments to individual patients and improve long-term outcomes in B-cell malignancies. DOI - https://doi.org/10.18632/oncotarget.28719 Correspondence to - Laura Hyland - laura.hyland@foresight-dx.com Video short - https://www.youtube.com/watch?v=8hdh3G5zvlc Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on Transfusion Medicine. Topics include noninvasive prenatal testing for red blood cell and platelet antigens, transfusion cases in sickle cell disease, and pregnant patients who are alloimmunized to RBC antigens. Find the full published review series in Volume 145 Issue 20 of Blood Journal.

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differentiation and development of neutropenia. Researchers describe the mechanisms and propose a treatment strategy for restoring granulopoiesis. Finally, ruxolitinib maintenance therapy after allogeneic transplant. In a phase 2 study, this treatment strategy was associated with low rates of chronic graft-versus-host disease. Investigators say the use of JAK inhibitors in this context warrants further study.Featured Articles: Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myelomaA new severe congenital neutropenia syndrome associated with autosomal recessive COPZ1 mutationsLow rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

In this deeply personal episode, Drs. Samantha and Samuel Siegel share their journey of navigating cancer, medical school, and family life together. From their time as medical students at Jefferson Medical College to the challenges they faced with Samuel's testicular cancer diagnosis and Samantha's battle with Hodgkin's Lymphoma, their story highlights the complexities of being both physicians and patients. Throughout their experiences, they uncovered significant gaps in cancer survivorship care, prompting them to become passionate advocates for change in the healthcare system.Join Samantha and Samuel as they discuss the struggles and triumphs of parenting through illness, managing health crises while continuing their careers, and the emotional toll of caring for one another. With their shared mission to improve survivorship care and elevate its importance within medical practice, this episode serves as an inspiring and thought-provoking conversation on resilience, advocacy, and the power of personal stories in driving change.About Our Guest:Samuel Siegel, MDPediatricianDignity Health Woodland ClinicSamuel Siegel is a general pediatrician in Woodland, CA serving a predominantly rural population, including immigrants from Mexico and Central America. He practices hospital medicine, seeing newborns during their birth hospitalization and he attends high risk deliveries.In his outpatient practice, Dr. Siegel has a special interest in pediatric obesity and nutrition and founded an annual healthy eating project called Home-Grown Health. There, he gives away 1000 vegetable starts, soil, and fertilizer each year to families in his community. He believes that allowing children to participate in the unique process of nurturing plants from seeds will more successfully promote healthy eating habits.He is also a patient who has learned to live a fulfilling life with chronic medical conditions since his early twenties including inflammatory bowel disease, treatment for cancer while in medical school, and a living donor liver transplant from his brother in 2016. He is a husband and partner to a physician-patient spouse and together they have three wonderful children.

In a conversation with CancerNetwork®, Viviana Cortiana, MS4, medical student in the Department of Medical and Surgical Sciences at the University of Bologna, and Yan Leyfman, MD, a resident physician from the Icahn School of Medicine of the Mount Sinai Health System, discussed their publication in the March 2025 issue of ONCOLOGY titled “Expanding horizons in T-cell lymphoma therapy: a focus on personalized treatment strategies.” Throughout the discussion, the authors spoke about the current lymphoma landscape, CAR T-cell therapy, and the evolving understanding of the tumor microenvironment. Specifically, Cortiana covered a shift from histology-based classification to molecular tumor type classification using next-generation sequencing, as well as a growing interest in biomarker-driven therapies. Regarding the limited efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in T-cell lymphoma, she listed potential advances in combination therapies for angioimmunoblastic T-cell lymphoma (AITL), which include combining P13K and HDAC inhibition as well as CD30- and TRBC1-targeting CAR T-cell therapies. Furthermore, Leyfman discussed strategies that “reprogram” the microenvironment to address malignant T cells, particularly through epigenetic and adoptive cell therapies. Leyfman concluded by discussing future implications for T-cell lymphoma treatment, emphasizing an emergence of precision medicines and armored CAR engineering strategies. Authors of the manuscript published in ONCOLOGY outlined the available treatment options for peripheral T-cell lymphoma (PTCL), which include targeted therapies through EZH2 inhibition, chemotherapy with CHOP, CAR T-cell therapies, and allogenic stem cell transplantation. Additionally, they highlighted encouraging results from clinical trials evaluating epigenetic-targeted therapies through the identification of molecular aberrations, which can help tailor treatments to individual patients.  Furthermore, the article explored limitations of chemotherapy as well as autologous stem cell transplantation (ASCT), which may not be feasible for older patients or those with comorbidities. Authors suggested that targeted therapies may enhance tumor specificity while reducing systemic toxicity. Given the risks associated with ASCT, they emphaisized a focus on the incorporation of optimized treatment strategies, such as novel pharmaceuticals and combination therapies, into clinical practice for patients with PTCL.

In this week's episode, we'll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickle cell trait, and wild-type hemoglobin. Featured Articles:Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia Babesiosis and Sickle Red Blood Cells: Loss of Deformability, Heightened Osmotic fragility and Hyper-vesiculation 

- Overview of Diffuse Large B-Cell Lymphoma - Staging & Grading - Current Standard of Care - Treatment Options for Resistant Disease - New & Emerging Treatment Approaches - The Role of Clinical Trials - How Research Contributes to Treatment Choices - Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain - The Increasing Role of Telehealth/Telemedicine Appointments - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions to Ask Our Panel of Experts

- Overview of Diffuse Large B-Cell Lymphoma - Staging & Grading - Current Standard of Care - Treatment Options for Resistant Disease - New & Emerging Treatment Approaches - The Role of Clinical Trials - How Research Contributes to Treatment Choices - Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain - The Increasing Role of Telehealth/Telemedicine Appointments - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions to Ask Our Panel of Experts

Find your Human Design variables for FREE here → https://www.vanesshenry.com/variable-calculator    Human Design shows us that we're each here to show up and operate differently energetically – in personality, relationships, work – but did you know that it affects how we show up physically, too?   Your Human Design variables tend to play a big role in why your body shows up the way it does when it comes to your health.   They can help you understand why you tend to have certain symptoms and issues… and how you can heal them in a way that will work for YOU.   Today, we get to hear all about it from my ~absolute favorite~ person to learn variable from, Vaness Henry! Vaness is a 6/2 ego manifestor, shamanic healer, writer, and cancer survivor. She's also an expert on the variables, and how they affect our health and wellbeing.   In the episode, we talked about…  Vaness's story: Getting diagnosed with Hodgkin's Lymphoma at 16, finding Human Design, and using her chart to understand her cancer experience The patterns between HD charts and chronic illness that Vaness has discovered (don't worry, this DOES NOT MEAN you will get sick!) Top 3 variable aspects to look at if you want to understand your symptoms, especially if they're chronic or just not going away Why a “healthy environment” is waaaaay more than location or your physical surroundings How your natural archetypes, personality, and energy play into your health (or lack of health) Vaness's solution for those who don't know their exact birth time, but still really want to play around with variable  Examples from both our charts, of course  

Enjoy a replay of Monday night's Patriots post-draft party co-hosted by Andrew and the Boston Herald's Doug Kyed. Together, they interview ESPN's Mina Kimes, Jason McCourty, Danny Kelly, Danny Heifetz, Phil Perry, Mike Giardi, Taylor Kyles, Michael Hurley, Sam Monson and Steve Palazzolo all about the Patriots draft and potential for next season. Donate at https://princesshallieforever.com — all proceeds go to Doug Kyed's Leukemia and Lymphoma fundraiser in honor of his daughter, Hallie. Pats Interference is presented by: Gametime! Take the guesswork out of buying NFL tickets with Gametime. Download the Gametime app, create an account, and use code CLNS for $20 off your first purchase. Download Gametime today. What time is it? Gametime! Terms apply. Go to ⁠⁠https://gametime.co⁠⁠ ! Learn more about your ad choices. Visit megaphone.fm/adchoices

In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first to fully characterize hematopoietic stem and progenitor cells in the adult human lung. After that: researchers develop a neural network-based probabilistic classifier, DLBclass, that assigns all diffuse large B-cell lymphomas into one of five genetic subtypes. It's an inclusive taxonomy that they say provides actionable genetic information in almost all patients with DLBCL. Finally, new insights on NETS, or neutrophil extracellular traps. In the liver vasculature, NET removal leads to secondary inflammation, resulting in new waves of NETS that may impact future infection. We'll review these and other findings from this recent mouse model study.Featured Articles:Decoding functional hematopoietic progenitor cells in the adult human lungDLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphomaDonor regulatory T-cell therapy to prevent graft-versus-host disease

In this episode of The Aging Well Podcast, Dr. Jeff Armstrong and Corbin Bruton are joined by Chris Vogelsang. Chris shares his inspiring journey through cancer diagnosis, treatment, and recovery. Diagnosed with Non-Hodgkin Lymphoma in 2008, Chris discusses the emotional impact of his diagnosis, the challenges he faced, and the importance of maintaining a positive attitude. He explains the innovative CAR-T therapy he underwent at Roswell Park Comprehensive Cancer Center in Buffalo, NY and reflects on the changes in his life post-treatment, emphasizing the value of family, relationships, and living in the moment. Chris offers advice to others battling cancer, highlighting the advancements in medical treatments and the importance of hope and support.https://www.roswellpark.org/

In this week's episode we'll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients with sickle cell disease.Featured Articles:PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute Myeloid Leukemia 17R-Resolvin D1 Protects Against Sickle Cell Related Inflammatory Cardiomyopathy in Humanized Mice 

In this episode of Hema Now, Jonathan Sackier is joined by John Riches, Clinical Reader in Cancer Immunometabolism at the Barts Cancer Institute and Honorary Consultant Haemato-oncologist. They explore how metabolic shifts drive lymphoma progression, the potential of immunotherapy, and what the future holds for treating lymphoid malignancies.  Timestamps:      00:00 – Introduction  01:46 – Riches' journey into haematology  03:42 – What is T cell exhaustion?  07:06 – The key role of metabolism in lymphoma  09:33 - Richter's syndrome  13:17 – Breakthroughs in immunotherapy  20:27 – The challenges of translational research  25:39 – B cells in autoimmune diseases  28:16 – The potential of breath biopsy  32:58 – Riches' three wishes for healthcare 

Featuring an interview with Ms Amy Goodrich, including the following topics: Presentation and management of follicular lymphoma (FL) (0:00) Case: A woman in her late 70s with heavily pretreated disease experiences complete response to mosunetuzumab (24:41) Case: A man in his early 60s with extensive diffuse large B-cell lymphoma and short response to CAR-T is successfully bridged to allogeneic transplant with glofitamab (30:15) Case: A man in his late 50s with transformed FL has limited treatment options due to lack of social support (45:51) Effects of bispecific antibodies in follicular and diffuse large B-cell lymphoma (52:53) NCPD information and select publications

Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. NCPD information and select publications here.

In this week's episode we'll learn about the role of autologous transplant for relapsed myeloma. In an updated analysis of the GMMG ReLApsE trial, salvage autologous transplant offered no survival benefit compared to control chemotherapy. These findings may have clinical implications in an era of alternative, and highly effective, treatment options. After that: Response to DDAVP, or desmopressin, in bleeding disorders. This study is the first large scale meta-analysis to assess the response rate to DDAVP in bleeding disorders. Authors provide new insights into determinants of response, which vary according to the disease type. Finally, turning to diffuse large B cell lymphoma. Germinal center B cells depend on the activity of DOT1 and EZH2 to maintain their pro-proliferative identity. New research shows that combined treatment with DOT1L and EZH2 inhibitors has synergistic activity in vitro.Featured Articles:Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialDDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysisTargeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma

In this How I Treat series episode Blood Associate Editor, Dr. Jason Gotlib speaks with Drs. Aaron Gerds, Andreas Reiter, and Claire Harrison. The conversation focuses on the work and contributions of these authors to How I Treat Myeloproliferative Neoplasms, and exciting advances in the treatment and management of MPNs. See the full How I Treat series in volume 145 issue 16 of Blood.

In this week's episode we'll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.Featured Articles:IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromesTargeting cell-surface VISTA expression on allospecific naïve T cells promotes toleranceEpcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at PeerView.com/JFE865. CME/MOC/NCPD credit will be available until April 18, 2026.Unlocking Efficacy, Expanding Access to CAR-T in Lymphoma and Myeloma: From Practice-Changing Evidence to Real-World and Outpatient Experiences In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), Legend Biotech, and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at PeerView.com/JFE865. CME/MOC/NCPD credit will be available until April 18, 2026.Unlocking Efficacy, Expanding Access to CAR-T in Lymphoma and Myeloma: From Practice-Changing Evidence to Real-World and Outpatient Experiences In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), Legend Biotech, and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at PeerView.com/JFE865. CME/MOC/NCPD credit will be available until April 18, 2026.Unlocking Efficacy, Expanding Access to CAR-T in Lymphoma and Myeloma: From Practice-Changing Evidence to Real-World and Outpatient Experiences In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), Legend Biotech, and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at PeerView.com/JFE865. CME/MOC/NCPD credit will be available until April 18, 2026.Unlocking Efficacy, Expanding Access to CAR-T in Lymphoma and Myeloma: From Practice-Changing Evidence to Real-World and Outpatient Experiences In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), Legend Biotech, and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at PeerView.com/JFE865. CME/MOC/NCPD credit will be available until April 18, 2026.Unlocking Efficacy, Expanding Access to CAR-T in Lymphoma and Myeloma: From Practice-Changing Evidence to Real-World and Outpatient Experiences In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), Legend Biotech, and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, use of odronextamab, a CD20×CD3 bispecific antibody, in patients with diffuse large B-cell lymphoma, or DLBCL, progressing after CAR T cell therapy. The study is the first to evaluate the efficacy and safety of this therapy in the post-CAR T cell treatment setting. Finally, we will recap findings from a study of a novel CAR T-cell product that utilizes specificity to two antigens common in diffuse large B-cell lymphoma.Featured Articles:Aging platelets shift their hemostatic properties to inflammatory functionsOdronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyDissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma

In this bonus episode of the Blood podcast, we'll hear from Dr. Nicole Thornton, senior author of the article “Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotype”, speaks with Blood Associate Editor Dr. Erica Wood about the discovery of the genetic basis for the inherited AnWj-negative blood group phenotype. The discovery that Mal protein is expressed on red blood cell membranes of AnWj-positive, but not AnWj-negative individuals, and that homozygous deletion in MAL causes the AnWj-negative blood group phenotype, helps answer a decades-old mystery related to the high prevalence red blood cell antigen AnWj and forms the basis of a new blood group system. 

Denna Arias from Energy Domain, Cory Mcintire from Wilbanks Reserve Corporation, and Greg Cohen from the Leukemia and Lymphoma Society (LLS) join the Philanthropy Series to discuss their personal journey's battling blood cancer, the advancements that have been made over the years, and what LLS is doing to raise awareness in order to help fund ongoing research that will ultimately end blood cancer once and for all. A big thanks to our 4 Minerals & Royalties Podcast Sponsors:--Tracts: If you are interested in learning more about Tracts title related services and software, then please call 281-892-2096 or visit https://tracts.co/ to learn more.--Riverbend Energy Group: If you are interested in discussing the sale of your Minerals and/or NonOp interests w/ Riverbend, then please visit www.riverbendenergygroup.com for more information--Farmers National Company: For more information on Farmer's land management services, please visit www.fncenergy.com or email energy@farmersnational.com--Oseberg: For more information on the software & data analytics tools that Oseberg has to offer, please visit www.oseberg.io.

In this week's episode, we'll learn more about using itacitinib for the prevention of graft vs host disease in haploidentical transplants, diagnosis and management of purpura fulminans, and results of a systematic review seeking evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait. Featured Articles:Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantationHow I diagnose and treat acute infection–associated purpura fulminansSickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review

In this week's episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, spoke with Ann S. LaCasce, MD, MMSc, an associate professor of medicine and a lymphoma specialist at Dana-Farber Cancer Institute in Boston, Massachusetts and Director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology. LaCasce shares her journey into hematologic oncology, shaped by early mentors—including her father—and how a passion for art history sparked her interest in pattern recognition and morphology, which are skills central to lymphoma diagnosis. Their discussion explores key advancements in Hodgkin and non-Hodgkin lymphoma management, including efforts to reduce long-term toxicity by minimizing radiation in early-stage Hodgkin lymphoma. LaCasce also highlights the incorporation of novel agents, such as brentuximab vedotin (Adcetris) and checkpoint inhibitors, into frontline regimens aimed at improving outcomes without increasing treatment burden. Park and LaCasce also discuss the importance of education and mentorship. She describes her work directing one of the country's largest hematology/oncology fellowship programs and her leadership in founding the international Women in Lymphoma network to foster collaboration and gender equity in the field. From clinical innovation to workforce development, LaCasce provides a comprehensive look into the role of multidisciplinary research, mentorship, and global engagement in advancing the future of lymphoma management.

In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome measure for sclerosis associated with chronic GVHD—graft-versus-host disease. The new symptom scale—currently undergoing validation studies—may provide valuable information regarding severity, functional impact, and response to therapy. Finally, a study of changes in population dynamic rates that underlie inflammation-associated myeloid bias. The work demonstrates the use of mathematical models to deliver critical biological insights and uncover underlying mechanisms.Featured Articles:MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialDevelopment of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosisPopulation dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases

In this episode, Liz and Michelle discuss the profound impact of prayer in the lives of Christian military women, particularly during challenging times. Michelle shares her personal journey through her son's lymphoma scare, her daughter's subsequent diagnosis, and her husband's battle with COVID. The conversation emphasizes the importance of community support, the power of prayer, and the need to remain deeply rooted in faith amidst trials. Michelle also introduces a new prayer booklet designed to help military families navigate their unique challenges through prayer. Instagram:   / plantingroots1   Facebook:   / plantingroots1   YouTube:    / @plantingroots1   Website: https://plantingroots.net/ "They will be like a tree planted by the water that sends out its roots by the stream. It does not fear when heat comes; its leaves are always green. It has no worries in a year of drought and never fails to bear fruit.” -Jeremiah 17:8

Featuring an interview with Ms Robin Klebig, including the following topics: Overview of the natural history and treatment landscapes of lymphoma subtypes (0:00) Structure and mechanisms of action of bispecific antibodies (23:41) Similarities and differences among the various approved and investigational CD20 x CD3 bispecific antibodies for non-Hodgkin lymphoma (28:14) Case: A man in his early 50s with multiagent/multiregimen-refractory follicular lymphoma who experienced disease progression with chimeric antigen receptor T-cell therapy now receives mosunetuzumab (39:14) Case: A woman in her mid 60s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives glofitamab (49:08) Case: A man in his mid 60s with R/R high-grade B-cell lymphoma with MYC and Bcl-2 rearrangements receives epcoritamab (52:57) Case: A man in his early 60s with composite lymphoma receives epcoritamab (56:55) NCPD information and select publications

Ms Robin Klebig from the Mayo Clinic in Rochester, Minnesota, discusses the emerging role of bispecific antibodies in the treatment of non-Hodgkin lymphoma. NCPD information and select publications here.

Ms Robin Klebig from the Mayo Clinic in Rochester, Minnesota, discusses the emerging role of bispecific antibodies in the treatment of non-Hodgkin lymphoma. NCPD information and select publications here.

Here's the latest CPG news happening right now on March 9th, 2025 including New Malk SKUs, Sweet Loren's Meteoric Rise, Expo West RecapMalk has released two new SKUs in multi-serve format: Coconut Malk and Soy Malk. These are both available in 32 oz bottles.Coconut MALK is hitting shelves nationwideSoy MALK is exclusive to Whole Foods Market and with 3 Simple Ingredients and 6g of naturally occurring protein per serving fills a much needed niche.They debuted both at Expo West this past weekThe cookie dessert brand Sweet Loren's is now on track to achieve $120M in revenue in 2025Loren Castle is the CEO and Founder. The then 22-year-old New York City native got a degree in communications and knew she liked health, wellness and business, “but I had no idea what I was going to do with my life,” she says. Post-graduation, she went back to New York but planned to move to L.A. permanently to see where life took her.Just months after graduating, however, Castle was diagnosed with stage 2 Hodgkin's Lymphoma, a cancer that attacks the immune system, and had to undergo six months of chemotherapy. Depressed, she began seeing a therapist who helped her see the moment as empowering and an opportunity. There were still ways in which she could take control.One such way was her diet — she could make sure to eat healthy even after her treatment. Castle began taking nutrition and cooking classes, but she quickly discovered something was missing: dessert. “I have a huge sweet tooth,” she says, and she couldn't find baked goods made with more whole foods that didn't use ingredients like bleached white flour, corn syrup and artificial chemicals.So Castle started trying to make healthier desserts for herself. Expo West 2025 is in the books. There were over 65,000 attendees. This was the first year where every exhibit hall opened at the exact same time. According to recent information, Expo West 2025 featured around 3,600 exhibitors (an increae from 3,000 last year) showcasing a wide range of natural and organic products across various categories like food, beverage, packaging, and wellness items.

A Cutaneous T-cell Lymphoma (CTCL) diagnosis can raise many questions, from understanding symptoms to exploring treatment options.  In this episode,… The post Cutaneous T-Cell Lymphoma (CTCL): From Diagnosis to Innovation first appeared on The Bloodline with LLS.

Morbidity & Mortality (M & M) are common case conferences to learn from unfortunate cases to improve care in the future. This episode looks at two recently published case reports. 1. Fatal tumor lysis syndrome following a lack of venetoclax ramp-up in AML: https://www.jhoponline.com/issue-archive/2024-issues/december-2024-vol-14-no-6/rapid-onset-of-fatal-tumor-lysis-syndrome-in-a-patient-with-acute-myeloid-leukemia-receiving-azacitidine-and-venetoclax-without-a-ramp-up-schedule-a-case-report 2. CD4+ T-cell lymphoma harboring a CAR integration into TP53: https://www.nejm.org/doi/full/10.1056/NEJMoa2411507

Show notes and links:  https://www.chrisbeatcancer.com/17-year-hodgkins-lymphoma-thriver-cortney-campbell-on-healing-holistically-her-new-a-z-natural-healing-handbook